Completed PHASE2 INTERVENTIONAL 3-arm NCT00388960

Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

Randomized Phase II Study of Amrubicin as Single Agent or in Combination With Cisplatin Versus Etoposide-cisplatin as First-line Treatment in Patients With Extensive Stage SCLC (ES)

Sponsor: Celgene

Conditions Small Cell Lung Cancer

Interventions Amrubicin Cisplatin Etoposide

Updated 9 times since 2017 Last updated: Nov 14, 2019 Started: Nov 1, 2006 Primary completion: Apr 1, 2010 Completion: Dec 1, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Small Cell Lung Cancer, this trial is completed. The trial is conducted by Celgene and has accumulated 9 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Dec 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Dec 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene

Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Antwerp, Belgium , Bebington, United Kingdom , Belfast, United Kingdom , Dundee, United Kingdom , Edegem, Belgium , Edinburgh, United Kingdom , Enschede, Netherlands , Gdansk, Poland , Genova, Italy and 13 more locations